Sermorelin vs Ipamorelin
Comparing GHRH analog sermorelin with growth hormone releasing peptide ipamorelin - two different approaches to stimulating GH release.
Last updated: January 28, 2026
Sermorelin
Ipamorelin
Overview
Sermorelin and ipamorelin both stimulate growth hormone release but through different receptor systems. Sermorelin is a GHRH analog that acts on the GHRH receptor, while ipamorelin is a growth hormone releasing peptide that acts on the ghrelin receptor. This fundamental difference has implications for their effects and side effect profiles.
Understanding these differences is important because these peptides are often discussed in anti-aging and research contexts.
Key Facts
| Aspect | Sermorelin | Ipamorelin |
|---|---|---|
| Class | GHRH Analog | GHRP (Ghrelin mimetic) |
| Structure | 29 amino acids | 5 amino acids |
| Target | GHRH receptor | GHS-R1a (Ghrelin receptor) |
| FDA Status | Previously approved (discontinued) | Not approved |
| Current Status | Used off-label/compounding | Research chemical |
Mechanism Comparison
| Aspect | Sermorelin | Ipamorelin |
|---|---|---|
| Receptor | GHRH-R | GHS-R1a |
| Natural Analog | GHRH(1-29) | Ghrelin mimetic |
| Action | Stimulates GH synthesis & release | Stimulates GH release |
| Selectivity | GHRH-specific | GH-selective among GHRPs |
Sermorelin Mechanism
- Truncated form of natural GHRH (first 29 of 44 amino acids)
- Contains full biological activity of native GHRH
- Acts directly on pituitary somatotrophs
- Stimulates both GH synthesis and release
- Maintains physiological GH pulsatility
Ipamorelin Mechanism
- Synthetic pentapeptide
- Acts on ghrelin receptor
- More selective than other GHRPs
- Minimal effect on cortisol/prolactin
- Does not strongly stimulate appetite
GH Release Profile
| Aspect | Sermorelin | Ipamorelin |
|---|---|---|
| GH Increase | 2-5x baseline | 2-4x baseline |
| Time to Peak | 30-60 minutes | 15-30 minutes |
| Duration | 2-3 hours | 2-3 hours |
| Pattern | Physiological pulse | Acute pulse |
Synergistic Use
Sermorelin and ipamorelin (or other GHRPs) are sometimes studied together because:
- Different receptor targets
- Potentially synergistic effects
- May produce larger GH pulses than either alone
- Different mechanisms complement each other
Selectivity Comparison
| Effect | Sermorelin | Ipamorelin |
|---|---|---|
| GH Release | Primary effect | Primary effect |
| Cortisol | No significant effect | Minimal effect |
| Prolactin | No significant effect | Minimal effect |
| Appetite | No significant effect | Minimal effect |
| Overall Selectivity | GHRH-specific | GH-selective (for a GHRP) |
Ipamorelin is notable among GHRPs for its selectivity, avoiding many side effects of other ghrelin mimetics.
Side Effect Profile
Sermorelin Side Effects
| Effect | Frequency | Notes |
|---|---|---|
| Injection Site Reactions | Common | Redness, swelling |
| Flushing | Occasional | Facial warmth |
| Headache | Occasional | Usually mild |
| Dizziness | Rare | Transient |
Ipamorelin Side Effects
| Effect | Frequency | Notes |
|---|---|---|
| Injection Site Reactions | Common | Typical for peptides |
| Headache | Occasional | Usually transient |
| Flushing | Occasional | Less than other GHRPs |
| Light-headedness | Occasional | Brief |
Comparative Safety Profile
| Factor | Sermorelin | Ipamorelin |
|---|---|---|
| Cortisol Disruption | No | Minimal |
| Prolactin Increase | No | Minimal |
| Appetite Stimulation | No | Minimal |
| Water Retention | Possible | Possible |
Evidence Quality
| Factor | Sermorelin | Ipamorelin |
|---|---|---|
| Human Trials | Multiple | Limited |
| FDA Review | Yes (previously approved) | No |
| Long-term Data | Some | Very limited |
| Publication Quality | Moderate | Low |
Sermorelin History
- FDA-approved 1997 for pediatric GH deficiency (Geref)
- Manufacturing discontinued 2008
- Currently available through compounding pharmacies
- Some peer-reviewed human data exists
Ipamorelin History
- Developed by Novo Nordisk
- Reached Phase 2 trials (post-operative ileus)
- Development discontinued
- Limited published human data
Regulatory Status
| Aspect | Sermorelin | Ipamorelin |
|---|---|---|
| FDA Status | Previously approved | Never approved |
| Current Availability | Compounding (US) | Research chemical |
| Medical Use | Off-label HRT clinics | Not indicated |
| WADA Status | Prohibited | Prohibited |
Compounded Sermorelin
In the US, sermorelin is available through:
- Compounding pharmacies
- Anti-aging clinics
- HRT clinics
- Requires prescription
Note: Compounded medications have less quality oversight than FDA-approved drugs.
Administration
| Aspect | Sermorelin | Ipamorelin |
|---|---|---|
| Route | Subcutaneous injection | Subcutaneous injection |
| Storage | Refrigerated | Refrigerated |
Clinical Applications (Research/Off-label)
| Use | Sermorelin | Ipamorelin |
|---|---|---|
| GH Deficiency | Yes (historically) | Not established |
| Anti-aging | Off-label use | Research |
| Body Composition | Studied | Limited data |
| Sleep Quality | Anecdotal | Anecdotal |
Comparison with Other Secretagogues
| Factor | Sermorelin | Ipamorelin | GHRP-6 | MK-677 |
|---|---|---|---|---|
| Receptor | GHRH-R | GHS-R1a | GHS-R1a | GHS-R1a |
| Selectivity | High | High | Low | Moderate |
| Appetite | No | Minimal | Strong | Strong |
| Cortisol | No | Minimal | Yes | Minimal |
| Route | Injectable | Injectable | Injectable | Oral |
Summary
| Factor | Sermorelin | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRP |
| Receptor | GHRH-R | GHS-R1a |
| Evidence Level | Moderate | Moderate |
| Selectivity | High | High (for GHRP) |
| Side Effects | Minimal | Minimal |
| Regulatory | Previously approved | Never approved |
Key Takeaways
- Different mechanisms: Sermorelin acts on GHRH receptor; ipamorelin on ghrelin receptor
- Both are selective: Minimal effects on cortisol, prolactin, and appetite
- Sermorelin has more history: Was FDA-approved and has more human data
- Ipamorelin is research-only: Never achieved regulatory approval
- Often combined: Different receptors allow potential synergy
- Both injectable: Neither has oral formulation
- Both prohibited in sport: WADA banned list includes both
- Variable quality: Sources outside regulated pharmacies have unknown purity
This comparison is for educational purposes only. Sermorelin (compounded) requires prescription. Ipamorelin is not approved by regulatory agencies.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.